These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18094214)

  • 21. The design and conduct of human studies to detect and quantify QT interval prolongation induced by new chemical entities.
    Camm AJ
    Fundam Clin Pharmacol; 2002 Apr; 16(2):141-5. PubMed ID: 12031066
    [No Abstract]   [Full Text] [Related]  

  • 22. The thorough QT study - do we need more of the same?
    Loke YK
    Br J Clin Pharmacol; 2016 Mar; 81(3):400-1. PubMed ID: 26692294
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity.
    Shah RR
    Fundam Clin Pharmacol; 2002 Apr; 16(2):147-56. PubMed ID: 12031067
    [No Abstract]   [Full Text] [Related]  

  • 24. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relation of increased short-term variability of QT interval to congenital long-QT syndrome.
    Hinterseer M; Beckmann BM; Thomsen MB; Pfeufer A; Dalla Pozza R; Loeff M; Netz H; Steinbeck G; Vos MA; Kääb S
    Am J Cardiol; 2009 May; 103(9):1244-8. PubMed ID: 19406266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
    Anchersen K; Clausen T; Gossop M; Hansteen V; Waal H
    Addiction; 2009 Jun; 104(6):993-9. PubMed ID: 19392907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Safe administration of new drugs].
    Schou J; Pelkonen O; Saano V
    Duodecim; 1996; 112(11):1013-6. PubMed ID: 10592998
    [No Abstract]   [Full Text] [Related]  

  • 28. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis.
    Dumotier BM; Deurinck M; Yang Y; Traebert M; Suter W
    Pharmacol Ther; 2008 Aug; 119(2):152-9. PubMed ID: 18462801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychotropic drugs associated with corrected QT interval prolongation.
    van Noord C; Straus SM; Sturkenboom MC; Hofman A; Aarnoudse AJ; Bagnardi V; Kors JA; Newton-Cheh C; Witteman JC; Stricker BH
    J Clin Psychopharmacol; 2009 Feb; 29(1):9-15. PubMed ID: 19142100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Terlipressin-induced ventricular arrhythmia.
    Urge J; Sincl F; Procházka V; Urbánek K
    Scand J Gastroenterol; 2008; 43(9):1145-8. PubMed ID: 18609153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Looks like snow.
    Yaganti V; Naik C; Jain D
    Am J Med; 2007 Mar; 120(3):236-8. PubMed ID: 17349445
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
    Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of long QTc interval in methadone maintenance patients.
    Fonseca F; Marti-Almor J; Pastor A; Cladellas M; Farré M; de la Torre R; Torrens M
    Drug Alcohol Depend; 2009 Jan; 99(1-3):327-32. PubMed ID: 18774239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating QTc in patients with advanced Parkinson's disease: overcoming artifact.
    Bloomfield DM
    Clin Pharmacol Ther; 2009 Apr; 85(4):365-6. PubMed ID: 19295536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QTc prolongation and/or oncology drug development: who's in danger?
    de Jonge M; Verweij J
    Eur J Cancer; 2008 Mar; 44(4):486-7. PubMed ID: 18272360
    [No Abstract]   [Full Text] [Related]  

  • 38. New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.
    Kinter LB; Siegl PK; Bass AS
    J Pharmacol Toxicol Methods; 2004; 49(3):153-8. PubMed ID: 15172011
    [No Abstract]   [Full Text] [Related]  

  • 39. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose haloperidol-associated QTc prolongation.
    Stepkovitch K; Heagle Bahn C; Gupta R
    J Am Geriatr Soc; 2008 Oct; 56(10):1963-4. PubMed ID: 19054204
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.